GI Effects Comprehensive Profile – 3 Day (Stool)
The GI Effects Comprehensive Profile is a 3-day stool panel assessing digestion and absorption, gut inflammation and immunology, and the microbiome, alongside screening for pathogenic bacteria, parasites, and yeast. It combines validated markers such as faecal calprotectin and pancreatic elastase-1 with microbiome and metabolic markers whose interpretation is more functional-medicine-oriented.
7
Biomarkers
Stool
Sample
14–21 business days
Turnaround
No
Fasting
What is the GI Effects Comprehensive (3-Day) test?
The GI Effects Comprehensive Profile is a multi-analyte stool panel that assesses three core domains of gastrointestinal function — digestion and absorption, gut inflammation and immunology, and the microbiome — alongside screening for pathogenic bacteria, parasites, and yeast. The 3-day collection samples across multiple bowel movements to improve representativeness for analytes and organisms that vary between stools. In the diagnostic landscape, the profile is positioned as a broad functional assessment of gut health rather than a single-target diagnostic test. It combines markers with strong clinical validation — such as faecal calprotectin for inflammation and pancreatic elastase-1 for exocrine insufficiency — with microbiome and metabolic markers whose interpretation is more functional-medicine-oriented and less standardised in mainstream practice. Practitioners order it to investigate chronic or complex gastrointestinal symptoms, to characterise digestion, inflammation, and microbial balance together, and to guide individualised dietary and microbiome-directed interventions. Results are interpreted as a composite picture, with the validated and the exploratory markers weighted accordingly.
What does the GI Effects Comprehensive (3-Day) test measure?
Pancreatic elastase-1 is a protease secreted by the exocrine pancreas that remains stable through intestinal transit and is concentrated in stool, making faecal levels a reliable indirect marker of pancreatic exocrine output. It is not degraded en route and correlates with overall enzyme secretion.
Faecal elastase-1 is the principal stool marker of exocrine pancreatic insufficiency, with low levels supporting impaired enzyme secretion as a cause of maldigestion, steatorrhoea, and nutrient malabsorption. It helps distinguish pancreatic from non-pancreatic causes of digestive symptoms.
Calprotectin is a calcium-binding protein released from neutrophils. Its concentration in stool rises in proportion to neutrophil migration into the gut lumen, making it a sensitive marker of intestinal inflammation that is stable in faeces for several days.
Faecal calprotectin distinguishes inflammatory bowel disease from functional disorders such as irritable bowel syndrome, where it is typically normal. Elevated levels warrant evaluation for organic inflammation, and it is widely used to triage the need for endoscopy and to monitor inflammatory activity.
Secretory IgA is the principal mucosal antibody, secreted across the gut epithelium to bind pathogens and antigens at the mucosal surface. Faecal levels are taken to reflect mucosal humoral immune activity.
Faecal secretory IgA is interpreted as a marker of gut mucosal immune status, with low levels suggested to indicate reduced mucosal defence and high levels an active mucosal immune response. Its clinical interpretation is less standardised than that of calprotectin or elastase. # REVIEWER FLAG: Evidence base for clinical decisions on sIgA is limited — reviewer to confirm positioning.
Short-chain fatty acids are produced by commensal bacterial fermentation of dietary fibre in the colon. Butyrate in particular is the principal energy source for colonocytes and supports epithelial integrity, while the overall pattern reflects fermentative microbial activity.
The total quantity and distribution of short-chain fatty acids provide an index of commensal fermentation and fibre metabolism. Reduced butyrate or altered distribution is interpreted as suboptimal fermentative function, informing dietary and microbiome-directed strategies.
Beta-glucuronidase is a bacterial enzyme that deconjugates compounds in the gut, including conjugated hormones and xenobiotics, influencing their enterohepatic recirculation. Its activity reflects aspects of the microbial metabolic environment.
Elevated beta-glucuronidase activity is interpreted as a marker of a microbial metabolic pattern that can increase deconjugation and reabsorption of compounds such as oestrogens and certain toxins. It is used in functional assessment of microbiome metabolic function. # REVIEWER FLAG: Clinical interpretation is functional-medicine-oriented — confirm positioning.
The profile quantifies a panel of commensal and keystone gut organisms by PCR, reflecting the composition of the resident microbiome across major bacterial groups associated with fermentation, mucosal health, and metabolic function.
The commensal abundance panel characterises the balance of the gut microbial community, identifying under- or over-representation of key groups that may inform dietary, prebiotic, and probiotic strategies. It is interpreted as a compositional snapshot rather than a diagnostic finding.
The profile screens for pathogenic and potentially pathogenic bacteria, parasites, and yeast using culture and molecular methods, identifying organisms associated with gastrointestinal infection or dysbiosis.
Detection of a recognised pathogen or significant yeast or parasite overgrowth supports an infective or dysbiotic contribution to gastrointestinal symptoms and can direct targeted treatment. Results are interpreted alongside symptoms and the wider profile.
Why is the GI Effects Comprehensive (3-Day) test ordered?
- Investigation of chronic or complex gastrointestinal symptoms — bloating, altered bowel habit, abdominal discomfort — where a broad functional assessment is sought
- Differentiation of inflammatory from functional bowel disorders using faecal calprotectin alongside the wider profile
- Assessment of suspected exocrine pancreatic insufficiency and maldigestion via pancreatic elastase-1
- Evaluation of suspected dysbiosis, with characterisation of commensal balance and fermentation markers
- Screening for enteric pathogens, parasites, or yeast overgrowth in patients with compatible symptoms or exposure
- Assessment of malabsorption or unexplained nutritional concerns where digestive function is in question
- Guiding and monitoring dietary, prebiotic, probiotic, or microbiome-directed interventions in integrative gastrointestinal care
- Workup of patients with irritable bowel syndrome-type presentations seeking a comprehensive functional evaluation
Sample collection and turnaround
Sample type
Stool
Fasting required
No
Collection method
At-home collection kit
Turnaround
14–21 business days
Collection notes
Samples are collected from separate bowel movements over three days to improve representativeness, using the kit-provided collection devices and preservatives. Avoid antimicrobials for the recommended washout period, and note recent probiotics, prebiotics, acid-suppressing therapy, and diet. Follow storage and shipping instructions precisely, as several analytes are sensitive to handling. # REVIEWER FLAG: Confirm full collection protocol, number of samples, preservatives, and washout guidance with Genova before publication.
Specimen requirements
Stool samples collected into the kit-provided tubes/preservatives across 3 days. # REVIEWER FLAG: Confirm exact specimen requirements, storage, and shipping conditions with Genova.
What can affect GI Effects Comprehensive (3-Day) results?
Antimicrobials alter microbial composition and can suppress detection of organisms, distorting the microbiome and pathogen results. A washout interval is advised. # REVIEWER FLAG: Confirm Genova's recommended washout period.
Recent probiotic or prebiotic intake transiently shifts measured commensal abundances and fermentation markers, which may not reflect the baseline microbiome.
Reduced gastric acidity alters the survival and distribution of organisms reaching the gut, changing the microbial picture independent of underlying pathology.
Recent bowel cleansing markedly disrupts the microbiome and luminal markers; collection should be delayed for an appropriate interval afterwards.
Fibre intake and dietary composition influence short-chain fatty acid production and fermentation markers, so results reflect recent diet as well as baseline function.
Improper storage, delayed shipping, or non-representative sampling can degrade analytes and skew results; the 3-day collection mitigates but does not eliminate variability. # REVIEWER FLAG: Confirm Genova storage and shipping requirements.
What do GI Effects Comprehensive (3-Day) results mean?
Elevated
Elevated faecal calprotectin points to intestinal inflammation and warrants evaluation for organic disease such as inflammatory bowel disease. Detection of pathogens, significant yeast or parasite overgrowth, or markedly altered commensal and metabolic markers supports a dysbiotic or infective contribution to be interpreted in clinical context.
Normal
Results within reference intervals across the domains indicate preserved digestion, absence of significant inflammation, and a balanced microbial picture by the criteria applied. Normal validated markers, particularly a normal calprotectin, make significant organic inflammation unlikely, though a normal profile does not exclude all pathology.
Reduced
Low pancreatic elastase-1 supports exocrine pancreatic insufficiency, while reduced commensal abundance, low short-chain fatty acids, or low butyrate proportion are interpreted as suboptimal fermentative and microbial function in the functional-assessment context.
Note: The profile mixes well-validated markers (calprotectin, pancreatic elastase-1) with microbiome and metabolic markers whose clinical interpretation is less standardised and more functional-medicine-oriented; these should be weighted differently. Results are influenced by recent diet, antimicrobials, probiotics, and acid suppression, and represent a snapshot subject to biological variability despite the 3-day collection. The profile is a composite functional assessment, not a standalone diagnostic, and abnormal exploratory markers should not be over-interpreted in isolation. # REVIEWER FLAG: Reviewer to confirm the platform's positioning on validated vs exploratory markers within this profile.
Frequently asked questions
It is a 3-day stool panel assessing digestion and absorption, gut inflammation and immunology, and the microbiome, alongside screening for pathogenic bacteria, parasites, and yeast. It combines validated markers with microbiome and metabolic markers in a single composite assessment.
How to access the GI Effects Comprehensive (3-Day) test
The GI Effects Comprehensive (3-Day) reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: June 3, 2026
Last reviewed: June 3, 2026
- D'Amico F, et al. Faecal calprotectin: from diagnosis to monitoring in inflammatory bowel disease. J Crohns Colitis. (2018)
- Vanga RR, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. (2018)
- Rios-Covian D, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. (2016)
- Konturek PC, et al. Gut microbiota and gastrointestinal disorders. J Physiol Pharmacol. (2015)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.